#United States #Alameda #Avian Influenza #Alveo Technologies #Royal GD

Alveo Technologies and Royal GD's Innovative Partnership for Animal Diagnostics

Alveo Technologies, Inc., a front-runner in the realm of molecular sensing and diagnostics, has officially announced a long-term partnership with Royal GD, a distinguished entity in animal health with a century of expertise. This collaboration aims to broaden their joint offerings, particularly in the area of rapid, point-of-need diagnostics for animal diseases.

The focus of their initial joint effort has been the development of the Alveo Sense™ Poultry Avian Influenza test. With avian influenza—a significant global health concern—this partnership seeks to provide effective tools for monitoring and containing such diseases. The urgency of developing reliable diagnostic methods is underscored by the increasing occurrence of emerging animal diseases that threaten food safety and security.

As part of their agreement, Alveo will be leveraging Royal GD's extensive distribution network to bring their newly launched avian influenza test to customers in both the Middle East and Northern Africa. The product was introduced in the EU in late 2024 and is already making waves in the agricultural industry. Royal GD will further serve as a crucial partner in the continued development and global distribution of these innovative diagnostic solutions.

The features of the Alveo Sense avian influenza test are noteworthy; it can detect Avian Influenza Type A, H5, H7, or H9 with remarkable accuracy—showing over 99% specificity and 98.3% sensitivity for H5. The test processes samples from both cloacal and oropharyngeal sources in less than 45 minutes, which is a significant leap forward from traditional methods that often required shipping samples to distant laboratories, resulting in delays that could hinder timely responses to virus outbreaks.

Moreover, results from the tests can be uploaded in real-time via Alveo's Alveo Vista™ portal, increasing transparency and enabling public health officials to react swiftly. This streamlining of diagnostics is particularly necessary considering the severe economic impacts of avian influenza. The outbreak has resulted in the deaths of over 280 million birds worldwide from culling and natural causes, significantly affecting the poultry industry and altering market dynamics.

In recent years, the need for rapid testing became even clearer as vaccination methods, while protective, do not prevent birds from carrying the virus. Thus, distinguishing between vaccinated birds and those that have contracted the disease becomes paramount. The DIVA (differentiating infected from vaccinated animals) strategy that the Alveo Sense technology supports will assist producers and veterinarians in maintaining flock health while preventing the spread of infection.

Wim Kieftenbeld, from Royal GD, remarked on the partnership's success in creating a leading-edge rapid molecular diagnostic. The technology not only addresses immediate needs but also lays the groundwork for tackling future zoonotic diseases. The ability to quickly identify infections means that stakeholders can take preventive measures far more effectively than was previously possible.

With the stakes of animal health and food safety at an all-time high, the collaboration between Alveo and Royal GD is set to catalyze significant advancements in the field. Their plans extend beyond avian influenza diagnostics; they aim to innovate testing protocols for other animal diseases as well. This ambition resonates strongly with stakeholders across the agricultural sector, who are eager for solutions that enhance health management and disease containment.

The Alveo Sense Poultry Avian Influenza test will be featured at the upcoming VIV Asia in Bangkok from March 12 to 14, offering an opportunity for more industry professionals to experience the innovations firsthand. This partnership is not just improving diagnostics; it is paving the way for more resilient agricultural practices worldwide.

In essence, the collaboration marks a significant step forward in animal health diagnostics, stressing the importance of agile, on-the-ground solutions in a rapidly changing global landscape. As they develop more tools to combat animal diseases, the combined expertise of Alveo Technologies and Royal GD will drive progress toward ensuring a secure food supply for the future.

For more about Alveo Technologies and their breakthroughs in diagnostics, visit Alveo Technologies.

About Alveo Technologies

Alveo Technologies is committed to making molecular diagnostics easily accessible, thereby helping to mitigate the impacts of pathogens through early detection. With their innovative platform, they aim to transform the landscape of food safety and health management around the globe.

About Royal GD

Royal GD is a Netherlands-based leader in animal health, providing comprehensive veterinary services and leveraging innovative technologies for early disease detection and prevention.